0.407

17.63% 0.061

After Hours: .41 0.003 +0.74%

Hcw Biologics Inc (HCWB)

Overview News Price History Financials Discussions Forecast

Hcw Biologics Inc stock is traded at $0.407, with a volume of 706.81K. It is up +17.63% in the last 24 hours and down -21.14% over the past month. HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Previous Close:

$0.346

Open:

$0.35

24h Volume:

706.81K

Relative Volume:

0.09

Market Cap:

$2.74M

Revenue:

$54,200

Net Income/Loss:

$-22.30M

P/E Ratio:

-0.0345

EPS:

-11.793

Net Cash Flow:

$-13.39M

1W Performance:

+24.01%

1M Performance:

-21.14%

6M Performance:

-90.62%

1Y Performance:

-95.13%

1-Day Range:

$0.35

$0.407

1-Week Range:

$0.3024

$0.407

52-Week Range:

$0.25

$17.80

Hcw Biologics Inc Stock (HCWB) Company Profile

Name

Hcw Biologics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

954-842-2024

Address

2929 N COMMERCE PKWY, MIRAMAR

Employee

Twitter

Next Earnings Date

2026-04-03

Latest SEC Filings

HCWB's Discussions on Twitter

Compare HCWB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HCWB Hcw Biologics Inc	0.407	2.33M	54,200	-22.30M	-13.39M	-11.79
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Hcw Biologics Inc Stock (HCWB) Latest News

Apr 11, 2026

HCWB SEC FilingsHcw Biologics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 11, 2026

Apr 09, 2026

EV Market: What is HCW Biologics Incs revenue forecast2026 Performance Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

Trading Recap: Can HCW Biologics Inc stock double in the next yearDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN

Apr 07, 2026

Apr 02, 2026

Growth Recap: Will HCW Biologics Inc outperform tech stocksEarnings Risk Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn

Apr 02, 2026

Mar 31, 2026

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - The Manila Times

Mar 31, 2026

HCW Biologics Q4 revenue drops sharply on license suspension - TradingView

Mar 31, 2026

HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026

HCW Biologics (NASDAQ: HCWB) outlines immunotherapy pipeline, deals and IP - Stock Titan

Mar 31, 2026

HCW Biologics (NASDAQ: HCWB) 2025 loss, going concern and Nasdaq risk - Stock Titan

Mar 31, 2026

Hair-loss trial starts as HCW Biologics warns on funding runway - Stock Titan

Mar 31, 2026

HCW Biologics Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025 - marketscreener.com

Mar 31, 2026

Mar 30, 2026

Growth Value: Is HCW Biologics Inc gaining market shareDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn

Mar 30, 2026

Mar 29, 2026

Forecast Cut: Will HCW Biologics Inc benefit from green energy policiesWeekly Stock Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn

Mar 26, 2026

HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN

Mar 26, 2026

Mar 25, 2026

HCW Biologics (HCWB) Projected to Post Earnings on Wednesday - Defense World

Mar 25, 2026

Mar 22, 2026

If You Invested $1,000 in Hcw Biologics Inc. (HCWB) - Stock Titan

Mar 22, 2026

Mar 18, 2026

HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart

Mar 18, 2026

HCW Biologics receives $7M upfront fee from China licensee By Investing.com - Investing.com South Africa

Mar 18, 2026

Mar 17, 2026

HCW Biologics Secures $7M License Deal for HCW11-006 - TipRanks

Mar 17, 2026

HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView

Mar 17, 2026

HCW Biologics receives $7M upfront fee from China licensee - Investing.com

Mar 17, 2026

[8-K] HCW Biologics Inc. Reports Material Event - Stock Titan

Mar 17, 2026

HCW Biologics Inc. Receives $7 Million Upfront License Fee from Beijing Trimmune Biotech for HCW11-006 Development and Commercialization Rights - Quiver Quantitative

Mar 17, 2026

Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic - TradingView

Mar 17, 2026

New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan

Mar 17, 2026

HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka

Mar 17, 2026

Mar 16, 2026

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Investing News Network

Mar 16, 2026

Small Cap Stocks To Keep An Eye OnMarch 16th - MarketBeat

Mar 16, 2026